Literature DB >> 11893144

Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer.

Rola Husni1, Ray Hachem, Hend Hanna, Issam Raad.   

Abstract

To determine the risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer, we conducted a case-control study. According to multivariate analysis, the only significant factors were neutropenia (< 500 cells/mm3) for more than 1 week and the use of oral vancomycin. Therefore, colonized neutropenic patients with cancer who have previously used oral vancomycin are most prone to VRE infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893144     DOI: 10.1086/502016

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Outbreak of vancomycin-resistant enterococcus colonization among pediatric oncology patients.

Authors:  Sheila M Nolan; Jeffrey S Gerber; Theoklis Zaoutis; Priya Prasad; Susan Rettig; Kimberly Gross; Karin L McGowan; Anne F Reilly; Susan E Coffin
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

2.  Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient.

Authors:  Imad Dibo; Satish K Pillai; Howard S Gold; Maria R Baer; Meir Wetzler; James L Slack; Peggy A Hazamy; Donna Ball; Chiu Bin Hsiao; Philip L McCarthy; Brahm H Segal
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection.

Authors:  Melissa A Kinnebrew; Carles Ubeda; Lauren A Zenewicz; Nichole Smith; Richard A Flavell; Eric G Pamer
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

4.  Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.

Authors:  Pedro Torres-Gonzalez; Miguel Enrique Cervera-Hernandez; María Dolores Niembro-Ortega; Francisco Leal-Vega; Luis Pablo Cruz-Hervert; Lourdes García-García; Arturo Galindo-Fraga; Areli Martinez-Gamboa; Miriam Bobadilla-Del Valle; Jose Sifuentes-Osornio; Alfredo Ponce-de-Leon
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  Empiric vancomycin use in febrile neutropenic oncology patients.

Authors:  Jessica Libuit; Andrew Whitman; Rebecca Wolfe; Casey S Washington
Journal:  Open Forum Infect Dis       Date:  2014-04-10       Impact factor: 3.835

6.  Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients.

Authors:  Matthew Snyder; Yanina Pasikhova; Aliyah Baluch
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Creation and Internal Validation of a Clinical Predictive Model for Fluconazole Resistance in Patients With Candida Bloodstream Infection.

Authors:  Adriana M Rauseo; Margaret A Olsen; Dustin Stwalley; Patrick B Mazi; Lindsey Larson; William G Powderly; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2022-08-30       Impact factor: 4.423

8.  Results of Four-Year Rectal Vancomycin-Resistant Enterococci Surveillance in a Pediatric Hematology-Oncology Ward: From Colonization to Infection.

Authors:  Hacer Aktürk; Murat Sütçü; Ayper Somer; Serap Karaman; Manolya Acar; Ayşegül Ünüvar; Sema Anak; Zeynep Karakaş; Aslı Özdemir; Kutay Sarsar; Derya Aydın; Nuran Salman
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

9.  Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting.

Authors:  Ouli Xie; Monica A Slavin; Benjamin W Teh; Ashish Bajel; Abby P Douglas; Leon J Worth
Journal:  BMC Infect Dis       Date:  2020-03-18       Impact factor: 3.090

Review 10.  Advances and Prospects in Vaccine Development against Enterococci.

Authors:  Ermioni Kalfopoulou; Johannes Huebner
Journal:  Cells       Date:  2020-11-02       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.